Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-29

Study Completion Date

2021-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586

Rett Syndrome RTT

TERMINATED PHASE3

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104

Seizure in Participants With Tuberous Sclerosis Complex Seizure in Participants With Dravet Syndrome Seizure in Participants With Lennox-Gastaut Syndrome

TERMINATED PHASE3

Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study

NCT05184478

Tourette Syndrome in Adolescence

COMPLETED PHASE1/PHASE2

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

NCT02318563

Dravet Syndrome

WITHDRAWN PHASE3

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

NCT03633058

Rett Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rett Syndrome RTT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 milligrams per kilogram per day (mg/kg/day) GWP42003-P

100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).

Group Type EXPERIMENTAL

GWP42003-P

Intervention Type DRUG

GWP42003-P presented as an oral solution containing cannabidiol

15 mg/kg/day GWP42003-P

100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).

Group Type EXPERIMENTAL

GWP42003-P

Intervention Type DRUG

GWP42003-P presented as an oral solution containing cannabidiol

Placebo

Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo oral solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GWP42003-P

GWP42003-P presented as an oral solution containing cannabidiol

Intervention Type DRUG

Placebo

Matching placebo oral solution

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cannabidiol CBD Epidiolex CBD-OS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant (if possessing adequate understanding, in the investigator's opinion) and/or their parent(s)/legal representative is willing and able to give informed consent/assent for participation in the trial.
* Participant and their caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
* Participant must weigh at least 10 kilograms.
* Clinical diagnosis of Rett syndrome (typical or atypical), defined according to RettSearch Consortium criteria
* Confirmed pathogenic genetic mutation of the MECP2 gene
* Participant must be post-regression (≥ 6 months since last loss of hand use or verbal language or gross motor regression).
* Participant must have a disease severity of between 10 and 36, defined according to the Clinical Severity Scale (CSS).
* All medications or interventions (including antiepileptic drugs \[AEDs\] and non-pharmacological interventions - dietary supplements, probiotics, physical therapy, speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4 weeks prior to screening and the participant/caregiver must be willing to maintain a stable regimen throughout the trial.
* Ability to swallow the investigational medicinal product (IMP) provided as a liquid solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed)
* Participant and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
* Participant and/or parent(s)/legal representative is willing to allow the participant's primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial, if the primary care practitioner/consultant is different than the investigator.

Exclusion Criteria

* Participant has clinically significant abnormal laboratory values, in the investigator's opinion.
* Participant is taking more than 2 concurrent AEDs.
* Any history of suicidal behavior or any suicidal ideation in the last month or at screening
* Clinically relevant abnormalities in the electrocardiogram (ECG) measured at screening or randomization
* Concurrent cardiovascular conditions which will, in the investigator's opinion, interfere with the ability to assess their ECGs or put the participant at risk because of participation in the trial
* First or second degree relative with a history of significant ECG abnormalities, in the opinion of the investigator (e.g. premature cardiac arrest, sudden death)
* Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP (active or placebo), such as sesame oil
* Participant has moderately impaired hepatic function at screening, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × upper limit of normal (ULN) or total bilirubin \> 2 × ULN.
* Participant is of childbearing potential, unless willing to ensure that they or their partner use a highly effective method of birth control (e.g., combined \[estrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, or transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, or implantable\], intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 3 months thereafter.
* Pregnant (positive pregnancy test) or lactating
* Received an IMP within the 3 months prior to screening
* Participant has been taking felbamate for less than 1 year prior to screening.
* Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS \[GWP42003-P\]) within the 3 months prior to screening and is unwilling to abstain for the duration of the trial
* Participant has a positive delta-9-tetrahydrocannabinol (THC) test at screening.
* Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, may influence the result of the trial, or the participant's ability to participate in the trial
* Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if she took part in the trial
* Participant has been previously randomized into this trial.
* Participant has traveled outside the country of residence planned during the trial.

Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No